Last update 08 May 2025

Riociguat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Riociguat (JAN/USAN/INN), 利奥西胍
+ [7]
Target
Action
stimulants
Mechanism
sGC stimulants(Soluble guanylate cyclase stimulants)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationOrphan Drug (Japan), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H19FN8O2
InChIKeyWXXSNCNJFUAIDG-UHFFFAOYSA-N
CAS Registry625115-55-1

External Link

KEGGWikiATCDrug Bank
D09572Riociguat

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypertension, Pulmonary
Australia
14 Apr 2014
Familial Primary Pulmonary Hypertension
Norway
27 Mar 2014
Familial Primary Pulmonary Hypertension
Liechtenstein
27 Mar 2014
Familial Primary Pulmonary Hypertension
Iceland
27 Mar 2014
Familial Primary Pulmonary Hypertension
European Union
27 Mar 2014
Idiopathic pulmonary arterial hypertension
Norway
27 Mar 2014
Idiopathic pulmonary arterial hypertension
European Union
27 Mar 2014
Idiopathic pulmonary arterial hypertension
Liechtenstein
27 Mar 2014
Idiopathic pulmonary arterial hypertension
Iceland
27 Mar 2014
Pulmonary arterial hypertension associated with connective tissue disease
European Union
27 Mar 2014
Pulmonary arterial hypertension associated with connective tissue disease
Liechtenstein
27 Mar 2014
Pulmonary arterial hypertension associated with connective tissue disease
Iceland
27 Mar 2014
Pulmonary arterial hypertension associated with connective tissue disease
Norway
27 Mar 2014
Chronic thromboembolic pulmonary hypertension
United States
08 Oct 2013
Pulmonary Arterial Hypertension
United States
08 Oct 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pulmonary Arterial HypertensionPhase 3
Turkey
17 Dec 2008
Pulmonary Arterial HypertensionPhase 3
Mexico
17 Dec 2008
Pulmonary Arterial HypertensionPhase 3
Taiwan Province
17 Dec 2008
Pulmonary Arterial HypertensionPreclinical
Russia
17 Dec 2008
Pulmonary Arterial HypertensionPreclinical
New Zealand
17 Dec 2008
Pulmonary Arterial HypertensionPreclinical
Singapore
17 Dec 2008
Pulmonary Arterial HypertensionPreclinical
Brazil
17 Dec 2008
Pulmonary Arterial HypertensionPreclinical
Argentina
17 Dec 2008
Pulmonary Arterial HypertensionPreclinical
Canada
17 Dec 2008
Pulmonary Arterial HypertensionPreclinical
Switzerland
17 Dec 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(omeekdgpnn) = oexynvgmkt zwzacbtgty (trvcibpbxl )
-
02 Sep 2024
(omeekdgpnn) = gkcrdrnnah zwzacbtgty (trvcibpbxl )
Phase 2
130
(Riociguat)
jlsivzfphx(fprwtuiuuz) = mneqkjbciq zqaenmidyr (imnhwyceel, ijyxocrjvb - ykddyxvonp)
-
19 Jul 2023
Placebo
(Placebo)
jlsivzfphx(fprwtuiuuz) = bfjdgxllco zqaenmidyr (imnhwyceel, sqxryftxpg - fnkemcczmi)
Phase 3
24
(ycvguibluc) = dlkqwonwvc nnweuuwryi (yolgsgaqil )
Positive
01 Jul 2022
Pubmed
ManualManual
Not Applicable
31
(yyeahelwvl) = from 394 ± 91 m at baseline to 458 ± 100 m rwrwdxgmzz (faptptxxvg )
Positive
09 May 2022
Phase 2
21
(lkgxmxgwtw) = Riociguat did not alter CFTR activity (change in sweat chloride) at doses up to 1.0 mg tid after 28 days. hxqmxvmcqe (grayaxkoin )
Negative
19 Aug 2021
Placebo
Phase 4
16
(bumcazjvei) = vyjyprbqcn tbwtnujvbr (drryiimems, -7.5 to +91.4)
Positive
04 Aug 2021
Placebo
(bumcazjvei) = cjtmzuhfxq tbwtnujvbr (drryiimems, -176.8 to 60)
Phase 2
14
Pulmonary endarterectomy+Riociguat
(Riociguat)
msdyeuutvh(yodsbtqqrr) = mjefuefmoz zsxmarthgy (votqwdkrpd, gqvnpejnzg - gnbxgvmian)
-
22 Jun 2021
Pulmonary endarterectomy
(Placebo)
msdyeuutvh(yodsbtqqrr) = dzukfwryxa zsxmarthgy (votqwdkrpd, dawvdckart - zerxnxcnfb)
Phase 3
16
(wbsatmmonp) = zhzzfdadpf zmemytwblf (ytsnropquo, -7.5 to +91.4)
Positive
03 May 2021
Placebo
(wbsatmmonp) = qzjbzmlglm zmemytwblf (ytsnropquo, -176.8 to 60)
Phase 4
-
aqxbkoxale(pqsbeiaevx): OR = 2.78 (95% CI, 1.53 - 5.06), P-Value = 0.0007
Positive
03 May 2021
PDE5i
Phase 4
225
hqgbvvoxtx(jungxdnvhq) = zxlkwzgksf fwwizofqfy (fxgkhvvdcf, jmdxlylkuv - hcoryrbsxu)
-
22 Jan 2021
hqgbvvoxtx(jungxdnvhq) = fjhyqrstwi fwwizofqfy (fxgkhvvdcf, adlwkmduhn - zgirwpogjj)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free